IBRX261023C00008000
IBRX Oct 23 2026 8.00 Call
optionOPRA
EODOct 16, 2026
2.17USD+3.333%(+0.07)11Vol23OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
8
Expiration
Oct 23, 2026
DTE
3d
Moneyness
ITM
Intrinsic
$0.48
IBRX 8 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $2.17 | +3.33% | 11 | 23 |
| Oct 30, 2026 | 10d | $1.42 | -29.00% | 8 | 45 |
| Nov 6, 2026 | 17d | $1.85 | -31.23% | 10 | 507 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $1.75 | -28.57% | 129 | 1,315 |
| Nov 27, 2026 | 38d | $1.90 | -25.49% | 2 | 11 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Mar 19, 2027 | 150d | $3.00 | -11.76% | 59 | 1,300 |
| Apr 16, 2027 | 178d | $4.16 | +69.80% | 20 | 96 |
| May 21, 2027 | 213d | $3.00 | +13.21% | 2 | 3 |
IBRX Nearby Strikes · Oct 23, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 5 C | $5.10 | +82.14% | 1 | 1 | ITM |
| 5.5 C | $4.27 | +55.27% | 2 | 1 | ITM |
| 6 C | $4.53 | +0.00% | 1 | 1 | ITM |
| 6.5 C | — | — | 0 | 0 | ITM |
| 7 C | $3.00 | +0.00% | 10 | 10 | ITM |
| 7.5 C | $2.47 | -14.83% | 13 | 24 | ITM |
| 8 C | $2.17 | +3.33% | 11 | 23 | ITM |
| 8.5 C | $1.82 | -4.71% | 11 | 95 | OTM |
| 9 C | $0.50 | -60.00% | 168 | 243 | OTM |
| 9.5 C | $0.28 | -65.00% | 263 | 438 | OTM |
| 10 C | $0.18 | -55.00% | 1,199 | 1,985 | OTM |
| 10.5 C | $0.15 | -57.14% | 227 | 1,477 | OTM |
| 11 C | $0.05 | -80.00% | 54 | 1,377 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.